JACOBIO PHARMACEUTICALS GROUP CO., LTD.

加科思藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1167)

VOLUNTARY ANNOUNCEMENT
JACOBIO COMPLETED FIRST PATIENT DOSAGE IN THE PHASE III CLINICAL TRIAL OF JAB-3312 IN COMBINATION WITH GLECIRASIB

This announcement is made by JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the "**Company**" or "**Jacobio**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders of the Company and potential investors about the latest business advancement of the Group.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company is pleased to announce that the Company has completed the first patient dosage in the Phase III clinical trial of KRAS G12C inhibitor Glecirasib in combination with the SHP2 inhibitor JAB-3312 versus standard care (chemotherapy plus anti-PD-1 antibody) in front-line KRAS G12C mutant non-small cell lung cancer (NSCLC). JAB-3312 is the first SHP2 inhibitor that entered a registration clinical trial globally.

The new drug application (NDA) of Glecirasib monotherapy for the second-line and beyond NSCLC with KRAS G12C mutation was granted Priority Review designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China on May 21, 2024.

According to data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2024, Glecirasib in combination with JAB-3312 resulted confirmed objective response rate (cORR) of 64.7% (66/102) and preliminary median progression-free survival (mPFS) of 12.2 months in the front-line NSCLC. The optimal dosing schedule Glecirasib at 800mg daily combined with JAB-3312 at 2mg daily one week on and one week off resulted a cORR of 77.4% (24/31), and 54.8% (17/31) of patients achieved a deep response with tumors shrinking by more than 50%. Regarding on the safety data from all study patients the incidence of grade 3 or 4 treatment-related adverse events (TRAE) was 43.8%, and there was no treatment-related death. The overall safety is manageable.

About Glecirasib

Glecirasib (JAB-21822) is a KRAS G12C inhibitor independently developed by Jacobio. A number of Phase I/II clinical trials of Glecirasib are currently ongoing in China, the United States and Europe for patients with advanced solid tumors harboring KRAS G12C mutation. These include a pivotal clinical trial in NSCLC in China, combination therapy trials with SHP2 inhibitor JAB-3312 in NSCLC and with cetuximab in colorectal cancer, and a registrational pivotal clinical trial of single agent for pancreatic cancer. The pancreatic cancer indication has obtained orphan drug designation in the United States and breakthrough therapy designation in China.

About JAB-3312

JAB-3312 is a highly selective SHP2 allosteric inhibitor with the best-in-class potential. Jacobio is currently conducting multiple clinical trials of JAB-3312 in China, the United States and Europe, including the combination therapy trial with Glecirasib. The Phase III study in combination with KRAS G12C inhibitor Glecirasib has been approved in China in February 2024.

About Jacobio

Jacobio is committed to developing and providing new and innovative products and solutions to improve patients' health. Our pipeline revolves around novel molecular targets on six major signaling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our immunostimulatory antibody-drug conjugate (iADC) Platform.

Warning under Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that Glecirasib (JAB-21822) and JAB-3312 will ultimately be successfully developed and marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company. Please visit www.jacobiopharma.com for more information.

By Order of the Board
JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Yinxiang WANG
Chairman

Hong Kong, August 7, 2024

As at the date of this announcement, the Board comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Ms. Yanmin TANG and Dr. Te-li CHEN as non-executive Directors, and Dr. Ruilin SONG, Dr. Bai LU and Dr. Ge WU as independent non-executive Directors.